Recite me link

All questions are shown as received by the Trust.
Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
a. ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)
b. Amivantamab
c. Atezolizumab Monotherapy
d. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
e. Dabrafenib + Trametinib
f. Docetaxel monotherapy or in combination with Carboplatin/Cisplatin
g. Durvalumab
h. Gemcitabine
i. Nitedanib + Docetaxel
j. Nivolumab
k. Osimertinib
l. Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
m. Paclitaxel
n. Pembrolizumab Monotherapy
o. Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
p. Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
q. Pemetrexed + Platinum (Carboplatin/Cisplatin)
r. RET Inhibitors (Pralsetinib, Selpercatinib)
s. Sotorasib
t. Tepotinib
u. Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
v. Other active systemic anti-cancer therapy
w. Palliative care only
Q2. Of all the NSCLC patients treated with nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with nivolumab?
Q3. Does your trust/health board participate in any clinical trials for non-small cell lung cancer (NSCLC)? If so, could you please provide the name of each active trial and the number of patients taking part.

Lung cancer.271023.docx